30.3 C
Vientiane
Thursday, July 10, 2025
spot_img
Home Blog Page 799

ZIM Launches Employer Branding Campaign in Hong Kong

HONG KONG, Feb. 26, 2025 /PRNewswire/ — ZIM Integrated Shipping Services Ltd. , a global leader in shipping and logistics, announced the launch of an Employer Brand Campaign in Hong Kong. Following a very successful campaign launched in the US in November 2024, the current initiative aims at attracting top talent to ZIM’s regional office in Asia. The campaign will showcase ZIM’s corporate culture and the values that make it a unique and dynamic workplace within this vital and impactful industry so central to Hong Kong and the entire region.


While ZIM ranks 9th globally, its market share in the Transpacific trade is significantly higher than its global share, and the company is an important player in this crucial global trade lane, underscoring the need to attract high-quality talent to meet the substantial demands in this region.

In the week leading up to the campaign, an internal launch event was held, involving a diverse range of employees who shared their career paths within the company. Employees and managers discussed the company’s efforts to operate according to its values, with a strong emphasis on sustainability. Notably, ZIM’s green ships, which now make up half of the fleet in Transpacific trade, were highlighted as a key component of the company’s portfolio.

Campaign Platforms and Focus

The campaign slogan, “Explore your potential. Be The Z Factor,” reflects ZIM’s recognition of the importance of its employer brand in attracting skilled individuals who align with the company’s ethos and culture. The campaign is based on messages developed through extensive research and direct input from current ZIM employees. By reflecting the voices of its team, ZIM’s new initiative aims to connect authentically with prospective employees who share its commitment to excellence and the distinctive Z Factor spirit.

The campaign aims to inform potential candidates about ZIM and why it is an excellent option for career development in the global economy and the dynamic and fast-paced shipping industry.

The campaign leverages various recruitment platforms, including social media, job search websites, and other channels to invite potential employees to join ZIM, with a focus on roles in customer service, sales, and other key positions supporting its rapidly growing global shipping services. It also aims to inform potential candidates about ZIM and why it is an excellent option for career development in a global industry.

Arik Elimelech, ZIM EVP HR and Organization, said, “As ZIM continues to grow and develop new services, we are excited to strengthen our brand and attract individuals who are ready to help us achieve our vision. This campaign is a meaningful step in building our team in Hong Kong, ensuring that we bring in not only the best talent but also those who genuinely identify with our culture and values. Our team is our strongest asset, and with their enthusiasm and dedication, I am confident this campaign will have a lasting impact.”

Yifat Ginzberg, ZIM Chief Marketing Officer, said: “We are applying marketing methodologies to our global recruitment efforts, using integrated metrics to measure both the immediate effectiveness of the campaign and long-term recruitment outcomes. By effectively communicating the company’s values and unique cultural principles, we succeed in recruiting employees who fit well and thrive within the company.”

ZIM’s Employer Brand Campaign is part of the company’s commitment to fostering a workplace where values, collaboration, and growth come together. ZIM is eager to welcome new talent and continue expanding its global impact, delivering innovative solutions across the shipping and logistics industry.

About ZIM

Founded in Israel in 1945, ZIM (NYSE: ZIM) is a leading global container liner shipping company with established operations in more than 90 countries serving approximately 33,000 customers in over 300 ports worldwide. ZIM leverages digital strategies and a commitment to ESG values to provide customers innovative seaborne transportation and logistics services and exceptional customer experience. ZIM’s differentiated global-niche strategy, based on agile fleet management and deployment, covers major trade routes with a focus on select markets where the company holds competitive advantages. Additional information about ZIM is available at www.ZIM.com.

ZIM Contacts:

Avner Shats
ZIM Integrated Shipping Services Ltd.
+972-4-865-2520
media@zim.com

Yifat Ginzberg
ZIM Integrated Shipping Services Ltd.
+972-4-865-2249
media@zim.com


 

 

 

Trina Storage Partners with Pacific Green, Energizing Australia’s Sustainable Ecosystem

SHANGHAI, Feb. 26, 2025 /PRNewswire/ — Trina Storage recently announced a significant collaboration with Pacific Green, a globally renowned energy storage developer. Together, they are working to construct the flagship project in South Australia—Limestone Coast North Energy Park. This partnership injects robust momentum into the advancement of sustainable energy in Australia and beyond.

Trina Storage and Pacific Green Partner for Limestone Coast North Energy Park Project
Trina Storage and Pacific Green Partner for Limestone Coast North Energy Park Project

Limestone Coast North Energy Park is a pivotal project for Pacific Green in Australia, with an enterprise value of AUD $460 million and a planned installed capacity of 250 MW/500 MWh. The asset is set to become one of the largest renewable energy parks in South Australia to date. Trina Storage, as the supplier of energy storage cells and integrator of battery cabinets, also assumes responsibility for the system performance guarantee and warranty, ensuring the reliability and durability of the entire energy storage system.

Australia’s unique climate, with significant seasonal variations in humidity and temperature, imposes stringent requirements on the anti-condensation and temperature control systems of energy storage solutions. Trina Storage has obtained multiple global safety certifications, including the world’s first UL certification for the thermal control performance of liquid-cooled energy storage containers. Additionally, its anti-condensation designs have successfully passed rigorous third-party testing, and it has earned TÜV NFPA69 explosion-proof ventilation system certification. These achievements have earned Trina Storage global recognition for delivering stable and safe power systems.

Du Yangfan, China Managing Director of Pacific Green Group, commended Trina Storage, stating, Trina Storage possesses a comprehensive quality control system, extensive experience, and a stellar reputation in the industry. After thorough evaluation, we are confident that Trina Storage is the optimal partner for this collaboration.”

Christo Hammes, COO of Pacific Green Group, added, “With partners like Trina Storage, we are confident in overcoming future challenges. This partnership represents a crucial step forward, and we see numerous opportunities for future collaboration with Trina Storage.”

Yang Bao, Global Marketing President of Trina Solar, remarked, “This collaboration with Pacific Green reaffirms our trustworthiness among global clients. Through our vertically integrated operations, Trina Storage has developed end-to-end cell-to-AC capabilities. Moving forward, we will accelerate strategic partnerships and continue creating value for our clients.”

As global demand for renewable energy continues to grow, the partnership between Pacific Green and Trina Storage is poised to lead the way in shaping the future of Australia’s renewable energy industry.

 

Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market

SHANGHAI, Feb. 26, 2025 /PRNewswire/ — On February 24, autonomous driving AI technology company Nullmax and global semiconductor solutions supplier Renesas Electronics officially signed a strategic partnership agreement in Shanghai. Zhe Sun, Head of Market Ecosystem at Nullmax, and Takeshi Fuse, Head of Business Development of High Performance Computing Product Group at Renesas, represented their respective companies at the signing ceremony.


Under this agreement, the two companies will engage in deep collaboration on Advanced Driver Assistance Systems (ADAS) applications, leveraging their respective strengths. By integrating Nullmax’s efficient platform-based AI software algorithms with the exceptional performance of Renesas’ R-Car V4 and R-Car X5 series chips, the partnership aims to develop reliable and user-friendly mass-production solutions for intelligent driving.

Zhe Sun, Head of Market Ecosystem at Nullmax, stated:

“We are pleased to establish this strategic partnership with Renesas. This collaboration will maximize Nullmax’s expertise in autonomous driving AI algorithms while capitalizing on Renesas’ robust chip performance. Together, we are committed to advancing breakthroughs and commercialization in autonomous driving technology. Through our close cooperation, we believe we can provide more efficient and reliable ADAS solutions for the global automotive industry, accelerating the widespread adoption and commercialization of smart driving technologies.”

Takeshi Fuse, Head of Business Development of High Performance Computing Product Group at Renesas at Renesas, commented:

“We are very delighted to have Nullmax as a partner in AD & ADAS applications, Nullmax’ proven perception solution enables fast implementation of AD & ADAS products built on Renesas SoCs, we will together bring more advance and more competitive products to support our customers make cars safer and smarter.”

As a key player in the autonomous driving industry, Nullmax has been committed since its establishment in 2016 to develop full-scenario autonomous driving applications through advanced AI algorithms and proprietary platform-based technology, driving the intelligent transformation of mobility. This strategic collaboration between Nullmax and Renesas will provide global automakers and Tier 1 suppliers with more competitive autonomous driving solutions and services.

Interlace at Consensus 2025: Card Solutions Connect Global Web3 Firms in the “Year of Payfi”

SINGAPORE, Feb. 26, 2025 /PRNewswire/ — From February 18 to 20, 2025, Consensus Hong Kong took place at the Hong Kong Convention and Exhibition Centre, attracting global attention from the Web3 and fintech communities in what many are calling the “Year of PayFi” in the crypto industry. During the event, Interlace, a leading fintech infrastructure provider, took the stage at the highly anticipated PayFi Summit 2025. Alongside prominent industry innovators such as the Solana Foundation, Huma Finance, and DePHY, Interlace offered insights into the evolving world of cross-border payments. The summit further explored PayFi’s cutting-edge applications and shed light on emerging industry trends, market opportunities, and the bright prospects ahead.

Interlace CEO Michael Wu
Interlace CEO Michael Wu

PayFi, short for Payment Finance, is an innovative technology and application model that integrates payment systems with financial services within the blockchain and cryptocurrency space. According to Lily Liu, Chair of the Solana Foundation, PayFi leverages blockchain technology to revolutionize payment systems, enabling more efficient, low-cost transactions while creating a new financial experience. Its goal is to develop more complex financial products and applications, building an integrated value chain that fosters the creation of a new financial ecosystem.

Technological innovation in financial services lies at the heart of Interlace’s mission. As a leader in card issuing infrastructure, Interlace delivers efficient, cost-effective, and multi-currency financial solutions that seamlessly bridge Web3 and Web2, connecting modern financial systems with emerging markets. By serving as a key enabler of stablecoin usage in cross-border payments, Interlace supports scalable, efficient financial transactions on a global scale.

Among the services offered are Card as a Service (CaaS), Banking as a Service (BaaS), and Wallet as a Service (WaaS), all of which allow businesses to effortlessly integrate financial capabilities into their existing platforms via APIs. Additionally, Interlace offers essential products like global accounts, acquiring services, and the issuance of both virtual and physical cards.

Michael Wu, CEO of Interlace, further elaborated on the company’s comprehensive “end-to-end” CaaS solution at the summit, which covers the entire process from wallet management to card issuance. Key functions include multi-Bin card issuance, deposit address generation, cryptocurrency KYT (Know Your Transaction), cardholder KYC (supporting both API integration and hosted mode), and secure, compliant infrastructure. This ensures that the flow of funds remains transparent and controllable throughout the entire process. Additionally, Interlace supports on-chain transfers, multi-account fund allocation, and efficient operations like top-ups, transfers, and card issuance, addressing the needs of a wide range of use cases.

In terms of CaaS, Interlace offers multi-BIN configurations to support clients’ global card issuance requirements. Its advanced risk control and anti-fraud system enable real-time transaction monitoring, safeguarding the security of funds. Interlace also provides a white-label API integration, allowing clients to customize card designs and enabling businesses to rapidly create unique brand differentiation.

Michael also emphasized that stablecoins are playing an increasingly crucial role in cross-border payments. Driven by technological innovation, Interlace provides industry-leading solutions that deliver the infrastructure for secure and efficient fund transfers, empowering institutions and clients to gain a competitive edge in the evolving integration of cryptocurrency with traditional payment systems.

Founded in 2019, Interlace has quickly established itself as a leader in the fintech space, earning the highest security certification in the international card payment industry, PCI-DSS Level 1. The company has also obtained licenses in key regions including the United States, and Lithuania. To date, Interlace has issued over 4.5 million cards and served 7,500 businesses worldwide, processing over 60 million transactions annually.

MBS Pioneers International Live Broadcast with TVU Solutions for Osaka Expo Warm-up

Leading up to Osaka Expo 2025, Japanese Broadcaster Successfully Deploys Innovative Broadcasting Solutions to Deliver Seamless Multi-National Cities Live Coverage

CUPERTINO, Calif., Feb. 25, 2025 /PRNewswire/ — Mainichi Broadcasting System (MBS) has pioneered groundbreaking international live coverage across multiple nations, leveraging TVU Networks’ innovative broadcasting solutions to showcase preparations for the Osaka Expo 2025. Opening April 13, 2025, the Expo will unite more than 150 countries and international organizations under the theme “Designing Future Society for Our Lives,” with projected attendance exceeding 28 million visitors.

In anticipation of this momentous occasion, MBS launched an ambitious broadcast initiative, establishing simultaneous live broadcast capabilities in multinational cities including Dubai and Istanbul through TVU’s advanced technology. The coverage from Dubai, host of the previous World Expo, proved particularly compelling—capturing both the city’s futuristic skyline and technological marvels alongside traditional souks and historic mosques, embodying the Expo’s mission of fostering cultural exchange.

Prior to deployment, MBS conducted rigorous equipment evaluations before selecting TVU’s comprehensive broadcasting solutions, with the TVU One backpack serving as their technical cornerstone, complemented by TVU Anywhere. The TVU One’s proprietary IS+ technology masterfully orchestrates multiple carrier network resources, creating a robust defense against signal disruptions in the field. Enhanced by H.265 intelligent variable bitrate encoding and Forward Error Correction (FEC), the system ensures high-fidelity, low-latency video transmission.

MBS Pioneers International Live Broadcast with TVU Solutions for Osaka Expo Warm-up
MBS Pioneers International Live Broadcast with TVU Solutions for Osaka Expo Warm-up

MBS reporters maximized TVU Anywhere’s mobility advantages, transforming smartphones into professional broadcasting tools for agile urban coverage. The application’s IS+ algorithm created robust transmission channels in high-traffic areas by seamlessly integrating 5G/4G and WiFi signals, ensuring uninterrupted delivery of high-quality live content.

“The synergy between TVU One and TVU Anywhere surpassed our performance expectations,” noted Teruhisa Kusanagi, Technical Production Center at MBS. “The system’s resilience in densely populated areas particularly impressed us. The IS+ technology maintained stable transmission even in demanding environments like the Dubai Mall and Spice Souk, reducing both setup time and costs.”

Rick Asahina, Senior Director of TVU Networks Japan, emphasized: “This pioneering broadcast demonstrates the full potential of our integrated solutions in supporting ambitious, multi-national live productions. MBS’s strategic deployment created a dynamic coverage approach balancing professional broadcast quality with operational flexibility. The successful transmission across major cities validates our commitment to developing resilient broadcast solutions capable of performing in any environment.”

WABCOWÜRTH RELIES ON GETAC: RELIABLE COMMERCIAL VEHICLE DIAGNOSTICS UNDER TOUGH CONDITIONS

GETAC S410 LAPTOPS IN USE IN COMMERCIAL VEHICLE DIAGNOSTICS THROUGHOUT EUROPE

TAIPEI, Feb. 26, 2025 /PRNewswire/ — WABCOWÜRTH Workshop Services GmbH, a joint venture between the Würth Group and the Commercial Vehicle Control Systems Division of the ZF Group, is using Getac S410 rugged laptops for increased efficiency of its multi-brand diagnostic systems for commercial vehicles across Europe. The powerful Getac rugged laptops were chosen for their high resilience, ease of use and excellent connectivity. They can be easily adapted to a wide range of EU requirements, so that several thousand devices have now been successfully in use since the beginning of 2024: in harsh workshop environments, outdoors, in a wide range of weather conditions and many other challenges.

Getac S410 laptops in use in commercial vehicle diagnostics throughout Europe.
Getac S410 laptops in use in commercial vehicle diagnostics throughout Europe.

WABCOWÜRTH specialises in multi-brand diagnostic solutions for commercial vehicles. Its W.EASY diagnostic systems, consisting of hardware and software, must reliably withstand the tough everyday working conditions in specialised workshops: in hot and cold conditions, during outdoor testing work, in all weathers or when operating with dirty hands. As well as being used on docking stations and bespoke trolley’s, they are also perched and/or rested directly onto a dirty engine bay. 

The robust solution from an other manufacturer that had been used to date no longer quite met the required functionality and flexibility, so WABCOWÜRTH performed extensive analysis procedures to decide on a new supplier. “The overall package of price, performance, value, quality & design and the excellent communication with Getac convinced us,” says Patrick Koch, Product Manager Diagnostic at WABCOWÜRTH.

Efficient maintenance: The advantages of the Getac Self-Maintainer programme

Another advantage is the Getac Self-Maintainer programme: spare parts can be obtained quickly and minor repairs can be carried out quickly and easily. Any device downtimes are reduced to a minimum.

Another decision-making factor was the first-class connectivity: Getac’s S410 communicates stably with the diagnostic interface via WLAN and Bluetooth, even over long distances. This is important for outdoor use. The S410 laptops have proven their value: They are powerful, user-friendly, have consistently easy-to-read displays even in outdoor use, and ensure high reliability – even in very harsh workshop environments or outdoors. “The devices work reliably and perfectly; so far we haven’t had a single complaint. So it couldn’t be better,” explains Patrick Koch. The close cooperation with Getac and its Platinum Partner PWA Electronic, through which WABCOWÜRTH purchases its devices, enables customised solutions at the highest level.

Eric Yeh, Managing Director of Getac Technology GmbH, says: “We are delighted with the successful deployment of our Getac S410 rugged laptops at WABCOWÜRTH – a further evidence of our commitment to not only providing leading rugged computing solutions, but also optimal, customer-centric, intelligent service capabilities.”

As a result, WABCOWÜRTH’s decision in favor of the Getac S410 was groundbreaking in helping to cope with the high demands of tough working conditions in a competitive European market. The S410s are helping the company to increase the efficiency of its diagnostic solutions and guarantee lasting customer satisfaction. WABCOWÜRTH is already planning further projects with Getac and PWA Electronic, possibly including the use of devices with significant technological innovations.

About Getac:

Getac Technology Corporation is a global leader in AI-capable rugged mobile technology and intelligent video solutions, including laptops, tablets, software, body-worn cameras, in-car video systems, digital evidence management and enterprise video analytics solutions. Getac’s solutions and services are designed to enable extraordinary experiences for frontline workers in challenging environments. Today, Getac serves customers in over 100 countries spanning defence, public safety, ambulance, fire & rescue, utilities, automotive, natural resources, manufacturing, transport, and logistics. Getac was recently recognized as one of Newsweek’s “World’s Most Trustworthy Companies” for 2024. For more information, visit: http://www.getac.com. Participate in the Getac Industry blog or follow the company on LinkedIn and YouTube

Getac and Getac logo are trademarks of Getac Holdings Corporation or its affiliates. Other brands or trademarks are the property of their respective owners. ©2025 Getac Technology Corporation.

FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review

MELBOURNE, Australia, Feb. 26, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET[1] imaging agent TLX250-CDx  (Zircaix®[2], 89Zr-DFO-girentuximab), granted a Priority Review and provided a PDUFA[3] date of 27 August 2025, paving the way for a U.S. commercial launch in 2025.

If approved, TLX250-CDx will become the first commercially available imaging agent to accurately and non-invasively diagnose and characterize clear cell renal cell carcinoma (ccRCC), the most common and one of the most aggressive sub-types of kidney cancer. It works by specifically binding to carbonic anhydrase IX (CAIX), a validated target protein expressed on 95% of ccRCC cells to produce images with high tumor-to-background ratio and high intra- and inter-reader consistency.

The BLA is based on Telix’s successful global Phase 3 ZIRCON[4] study, which demonstrated a sensitivity of 86%, specificity of 87% and a positive predictive value (PPV) of 93% for ccRCC, including in very small, difficult-to-detect lesions[5]. The results of this study were published in The Lancet Oncology in September 2024, in a peer-reviewed manuscript by Professor Brian Shuch (University of California, Los Angeles, UCLA) and colleagues[6]. The paper outlines the critical unmet need for a new, non-invasive technique that can accurately detect and differentiate ccRCC from other renal masses in patients and concluded that TLX250-CDx meets this need and ‘has the potential to be practice changing.’ 

Kevin Richardson, Chief Executive Officer, Precision Medicine, said, “We are delighted that the FDA has accepted this BLA as it moves us one step closer to bringing our breakthrough product to patients. We are aiming to revolutionize the management of kidney cancer, just as PSMA-PET/CT[7] scanning has changed the management of prostate cancer. By providing a more definitive clinical diagnosis for renal masses, we believe that Zircaix[2] will help physicians make more timely and confident patient management decisions and more quickly provide patients with a clear understanding of their disease and treatment options. Building further on Telix’s successful urology franchise, we are preparing to bring this powerful precision medicine product to market in 2025[8].”

About TLX250-CDx

TLX250-CDx (Zircaix®[2]) is an investigational PET agent that is under development for the diagnosis and characterization of ccRCC. Telix’s pivotal Phase 3 ZIRCON trial evaluating TLX250-CDx in 300 patients, of whom 284 were evaluable, met all primary and secondary endpoints, including showing 86% sensitivity and 87% specificity and a 93% PPV for ccRCC across three independent radiology readers[5]. Telix believes this demonstrated the ability of TLX250-CDx to reliably detect the clear cell phenotype and provide an accurate, non-invasive method for diagnosing and characterizing ccRCC. Confidence intervals exceeded expectations amongst all three readers, showing evidence of high accuracy and consistency of interpretation. 

As part of Telix’s commitment to access to medicine, the Company operates an expanded access program (EAP) in the U.S.[9], named patient programs (NPPs) in Europe, and a special access scheme (SAS) in Australia to allow continued access to TLX250-CDx outside of a clinical trial, to patients for whom there are no comparable or satisfactory alternate options. TLX250-CDx has not received a marketing authorization in any jurisdiction and is for investigational use only.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedInX and Facebook.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.

[1] Positron emission tomography.
[2] Brand name subject to final regulatory approval. 
[3] Prescription Drug User Fee Act.   
[4] Zirconium iRenal Cancer Oncology, ClinicalTrials.gov ID: NCT03849118.
[5] Telix ASX disclosures 7 November 2022.
[6] Shuch et al. Lancet Oncology. 2024.
[7] Imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography.
[8] Subject to regulatory approval.
[9] ClinicalTrials.gov ID: NCT06090331.

HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Feb. 26, 2025 /PRNewswire/ — HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaboration and license agreement with a business partner to advance novel therapies targeting corticotropin-releasing hormone (CRH) for various disorders.

Under the agreement, the partner gains exclusive global rights, excluding Greater China (mainland China, Taiwan, Hong Kong, and Macau), to develop and commercialize HAT001 (designated as HBM9013 by Harbour BioMed), a potent and selective anti-CRH-neutralizing antibody. In return, HBMAT is eligible to receive up to $395 million, including upfront, development, regulatory and commercial milestone payments, as well as tiered royalties on future net product sales. Additionally, HBMAT is also entitled to a warrant to receive minority interest in the partner.

HAT001/HBM9013 is designed to neutralize CRH for various disorders, including congenital adrenal hyperplasia (CAH). CAH is a group of autosomal recessive diseases due to mutations in genes that encode for enzymes necessary for synthesis of key adrenal hormones, which lead to serious health consequences. Current standard of care therapy of CAH was introduced more than 70 years ago. It has not changed significantly since and still has huge unmet medical needs. HAT001/HBM9013 aims to dramatically improve standard of care and improve patient outcomes. It has demonstrated strong preclinical efficacy in downregulating CRH-mediated induction of adrenocorticotropic hormone (ACTH) and is being advanced toward clinical development.

“This collaboration represents a pivotal step for HBMAT in our mission to deliver innovative solutions for patients facing challenging endocrine disorders. The completion of this transaction also marks Harbour BioMed’s partial exit from the first global NewCo we incubated,” said Dr. Jingsong Wang, Founder, Chairman & CEO of Harbour BioMed, and Chairman of BOD of HBMAT. “HAT001/HBM9013 has the potential to be a transformative therapy. With their expertise in drug development, our partner is well-positioned to help bring this therapy to patients worldwide.”

About HBM Alpha Therapeutics

HBM Alpha Therapeutics is a company presently developing antibody therapeutics aimed at the rare genetic disease congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). Its therapeutics could also be indicated for other endocrinological diseases related to the dysregulation and function of the hypothalamus-pituitary-adrenal (HPA) axis.

HBMAT was founded and incorporated in Delaware, USA in 2019. It is a joint venture between Harbour BioMed and Boston Children’s Hospital, an affiliate of Harvard Medical School. For more information, please visit www.hbmalphatx.com.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.
 
The proprietary antibody technology platforms Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, and HBICE® with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For further information, please refer to www.harbourbiomed.com.